Biogen Idec Earnings Preview: Get Ahead of the Analysts

Biogen Idec (NASDAQ:BIIB) will report earnings before markets open on Thursday, July 25th. Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.

Here is your Cheat Sheet to Biogen Idec Earnings:

Earnings Expectations: Analysts expect earnings of $1.93 per share on revenues of $1.62 billion. Currently, the company’s P/E ratio stands at 35.40.

Analyst Trends:

Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $2.13 and has not changed. For the current year, the average estimate is a profit of $8.23, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Biogen Idec has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 4,098 4,377 4,716 5,049 5,516
Diluted EPS ($) 2.65 3.35 3.94 5.04 5.76

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 1,420.95 1,385.55 1,417.94 1,415.10
Diluted EPS ($) 1.61 1.67 1.23 1.79

Past Performance:
Biogen Idec has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]